Effective Jan. 3, 2017, Ian Clark officially started work Shire’s new non-executive director.
Clark comes to the company from Genentech, Inc., part of the Roche Group) where he was Chief Executive Officer and Director and was Roche Group’s Head of North American Commercial Operations since January 2010.
“We are very pleased to announce Ian’s appointment at this important time; his in-depth knowledge of the biotechnology sector and breadth of operational experience stand to serve Shire well as we look forward to growing our business and addressing unmet patient needs world-wide,” said Susan Kilsby, Shire’s Chairman.
He has many years’ experience working in senior operational, sales and marketing settings in the pharmaceutical and healthcare fields. He has been on the Terra Via board of directors since April 2011 and is currently appointed as a Non-Executive Director, Chairman of the Compensation Committee and a member of the Nominating and Corporate Governance Committee.
“Shire has demonstrated commitment to being the global leader in rare diseases and to delivering value to its patients, physicians, shareholders and other stakeholders,” Clark said. “I look forward to working with Susan and the rest of the Board in pursuing a successful future for the Company.”
Shire is focused on developing products for people around the world with rare diseases and conditions in areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.
